Publisher： Bentham Science Publishers
E-ISSN： 1875-5607|8|10|968-975
ISSN： 1389-5575
Source： Mini Reviews in Medicinal Chemistry, Vol.8, Iss.10, 2008-09, pp. : 968-975
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Zonisamide (ZNS), a sulfonamide antiepileptic drug, is indicated as an adjunct therapy for partial seizure disorders with and without secondary generalization. ZNS has a favorable pharmacokinetic profile because of its rapid absorption and high bioavailability. Its activity is related to the blockade of voltage gated sodium and calcium channels, modulation of central dopaminergic, GABAergic, and serotonergic functions, as well as inhibition of carbonic anhydrase and monoamine oxidase B. ZNS has potential efficacy for an array of neuropsychiatric disorders including migraine and other headache syndromes, neuropathic pain, Parkinson's disease, essential tremor, stroke, obesity, anxiety, bipolar and bingeeating disorders.
Related content
The Role of Oxytocin in Neuropsychiatric Disorders
Current Medicinal Chemistry, Vol. 15, Iss. 7, 2008-03 ,pp. :
Access to resources
Recommend
Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design, Vol. 20, Iss. 11, 2014-04 ,pp. :